Epigenetic silencing of <scp>SALL</scp> 2 confers tamoxifen resistance in breast cancer
2019 · EMBO Molecular Medicine · 83 citations
https://doi.org/10.15252/emmm.201910638
M
Meisongzhu Yang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
40
Papers
815
Citations
14
h-index
16
i10-index
Meisongzhu Yang is an academic researcher. The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & Epigenetics and DNA Methylation & Cancer-related molecular mechanisms research. The author has an h-index of 14, co-authored 34 publications.
ORCID: 0000-0001-9725-4573Papers by this author
worksLPCAT1-mediated membrane phospholipid remodelling promotes ferroptosis evasion and tumour growth
2024 · Nature Cell Biology · 83 citations
https://doi.org/10.1038/s41556-024-01405-y
ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression
2021 · EBioMedicine · 77 citations
https://doi.org/10.1016/j.ebiom.2021.103558
ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer
2021 · Journal of Experimental & Clinical Cancer Research · 72 citations
https://doi.org/10.1186/s13046-021-01932-8
Specific Regulation of m<b>6</b>A by SRSF7 Promotes the Progression of Glioblastoma
2021 · Genomics Proteomics & Bioinformatics · 34 citations
https://doi.org/10.1016/j.gpb.2021.11.001
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
2022 · EMBO Molecular Medicine · 9 citations
https://doi.org/10.15252/emmm.202115618
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat